Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Removal of totally implanted venous access ports for suspected infection in the intensive care unit: a multicenter observational study.

Lecronier M, Valade S, Bigé N, de Prost N, Roux D, Lebeaux D, Maury E, Azoulay E, Demoule A, Dres M; GrrrOH (Group for Research in Respiratory Intensive Care Onco-Hematology).

Ann Intensive Care. 2018 Mar 27;8(1):41. doi: 10.1186/s13613-018-0383-9.

2.

A putative lateral flagella of the cystic fibrosis pathogen Burkholderia dolosa regulates swimming motility and host cytokine production.

Roux D, Schaefers M, Clark BS, Weatherholt M, Renaud D, Scott D, LiPuma JJ, Priebe G, Gerard C, Yoder-Himes DR.

PLoS One. 2018 Jan 18;13(1):e0189810. doi: 10.1371/journal.pone.0189810. eCollection 2018.

3.

Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence.

Phillips-Houlbracq M, Ricard JD, Foucrier A, Yoder-Himes D, Gaudry S, Bex J, Messika J, Margetis D, Chatel J, Dobrindt U, Denamur E, Roux D.

Int J Med Microbiol. 2018 Mar;308(2):290-296. doi: 10.1016/j.ijmm.2018.01.003. Epub 2018 Jan 5.

PMID:
29325882
4.

Airway microbiome research: a modern perspective on surveillance cultures?

Roux D, van Oort PM, Ricard JD, Bos LDJ.

Ann Transl Med. 2017 Nov;5(22):445. doi: 10.21037/atm.2017.08.05. Review.

5.

Erythroblastopenia in a critically ill influenza patient.

Valainathan SR, Roux D, Almire C, La Combe B.

Intensive Care Med. 2017 Aug;43(8):1150-1151. doi: 10.1007/s00134-017-4839-4. Epub 2017 May 12. No abstract available.

PMID:
28500452
6.

Immune Recognition of the Epidemic Cystic Fibrosis Pathogen Burkholderia dolosa.

Roux D, Weatherholt M, Clark B, Gadjeva M, Renaud D, Scott D, Skurnik D, Priebe GP, Pier G, Gerard C, Yoder-Himes DR.

Infect Immun. 2017 May 23;85(6). pii: e00765-16. doi: 10.1128/IAI.00765-16. Print 2017 Jun.

7.

Prevalence and Impact on Weaning of Pleural Effusion at the Time of Liberation from Mechanical Ventilation: A Multicenter Prospective Observational Study.

Dres M, Roux D, Pham T, Beurton A, Ricard JD, Fartoukh M, Demoule A.

Anesthesiology. 2017 Jun;126(6):1107-1115. doi: 10.1097/ALN.0000000000001621.

PMID:
28338483
8.

Antimicrobial strategy for severe community-acquired legionnaires' disease: a multicentre retrospective observational study.

Cecchini J, Tuffet S, Sonneville R, Fartoukh M, Mayaux J, Roux D, Kouatchet A, Boissier F, Tchir M, Thyrault M, Maury E, Jochmans S, Mekontso Dessap A, Brun-Buisson C, de Prost N.

J Antimicrob Chemother. 2017 May 1;72(5):1502-1509. doi: 10.1093/jac/dkx007.

PMID:
28204479
9.

Intra-alveolar hemorrhages due to left heart dysfunction and calcified constrictive pericarditis.

Hadjaj Y, Roux D, Justet A, Berquier G.

Intensive Care Med. 2017 Jun;43(6):929. doi: 10.1007/s00134-016-4672-1. Epub 2017 Jan 21. No abstract available.

PMID:
28110413
10.

An Oxygen-Sensing Two-Component System in the Burkholderia cepacia Complex Regulates Biofilm, Intracellular Invasion, and Pathogenicity.

Schaefers MM, Liao TL, Boisvert NM, Roux D, Yoder-Himes D, Priebe GP.

PLoS Pathog. 2017 Jan 3;13(1):e1006116. doi: 10.1371/journal.ppat.1006116. eCollection 2017 Jan.

11.

A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial.

Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, Boulain T, Ivanyi Z, János G, Garot D, Koura F, Zakynthinos E, Dimopoulos G, Torres A, Danker W, Montgomery AB.

Chest. 2017 Jun;151(6):1239-1246. doi: 10.1016/j.chest.2016.11.026. Epub 2016 Nov 24.

PMID:
27890714
12.

Septic shock with no diagnosis at 24 hours: a pragmatic multicenter prospective cohort study.

Contou D, Roux D, Jochmans S, Coudroy R, Guérot E, Grimaldi D, Ricome S, Maury E, Plantefève G, Mayaux J, Mekontso Dessap A, Brun-Buisson C, de Prost N.

Crit Care. 2016 Nov 6;20(1):360.

13.

Antibiotic resistance and virulence: Understanding the link and its consequences for prophylaxis and therapy.

Guillard T, Pons S, Roux D, Pier GB, Skurnik D.

Bioessays. 2016 Jul;38(7):682-93. doi: 10.1002/bies.201500180. Epub 2016 Jun 1. Review.

PMID:
27248008
14.

Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae.

Skurnik D, Roux D, Pons S, Guillard T, Lu X, Cywes-Bentley C, Pier GB.

J Antimicrob Chemother. 2016 Apr;71(4):927-35. doi: 10.1093/jac/dkv448. Epub 2016 Jan 7.

15.

Impact of Drug Resistance on Virulence and Fitness of Bacterial Pathogens.

Roux D, Pons S, Guillard T, Ricard JD, Pier GB, Skurnik D.

Crit Care Med. 2016 Jan;44(1):e50. doi: 10.1097/CCM.0000000000001330. No abstract available.

PMID:
26672941
16.

Emergence of Antimicrobial-Resistant Escherichia coli of Animal Origin Spreading in Humans.

Skurnik D, Clermont O, Guillard T, Launay A, Danilchanka O, Pons S, Diancourt L, Lebreton F, Kadlec K, Roux D, Jiang D, Dion S, Aschard H, Denamur M, Cywes-Bentley C, Schwarz S, Tenaillon O, Andremont A, Picard B, Mekalanos J, Brisse S, Denamur E.

Mol Biol Evol. 2016 Apr;33(4):898-914. doi: 10.1093/molbev/msv280. Epub 2015 Nov 26.

17.

Keep an ear to the ground, the answer's behind.

Do Vale J, Mezhari I, Oker N, Roux D.

Intensive Care Med. 2016 Mar;42(3):440-2. doi: 10.1007/s00134-015-4020-x. Epub 2015 Aug 20. No abstract available.

PMID:
26289009
18.

Fitness cost of antibiotic susceptibility during bacterial infection.

Roux D, Danilchanka O, Guillard T, Cattoir V, Aschard H, Fu Y, Angoulvant F, Messika J, Ricard JD, Mekalanos JJ, Lory S, Pier GB, Skurnik D.

Sci Transl Med. 2015 Jul 22;7(297):297ra114. doi: 10.1126/scitranslmed.aab1621.

PMID:
26203082
19.

Identification of Poly-N-acetylglucosamine as a Major Polysaccharide Component of the Bacillus subtilis Biofilm Matrix.

Roux D, Cywes-Bentley C, Zhang YF, Pons S, Konkol M, Kearns DB, Little DJ, Howell PL, Skurnik D, Pier GB.

J Biol Chem. 2015 Jul 31;290(31):19261-72. doi: 10.1074/jbc.M115.648709. Epub 2015 Jun 15.

20.

Effects of Proanthocyanidins on Adhesion, Growth, and Virulence of Highly Virulent Extraintestinal Pathogenic Escherichia coli Argue for Its Use to Treat Oropharyngeal Colonization and Prevent Ventilator-Associated Pneumonia.

Margetis D, Roux D, Gaudry S, Messika J, Bouvet O, Branger C, Ponnuswamy P, Oufella HA, Dreyfuss D, Denamur E, Ricard JD.

Crit Care Med. 2015 Jun;43(6):e170-8. doi: 10.1097/CCM.0000000000000972.

PMID:
25803655

Supplemental Content

Loading ...
Support Center